Compare Nebius Group NV (NBIS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Nebius Group NV trades at $221.12 (market cap $59.73B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Nebius Group NV is far larger — about 2.4× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 24 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| NBIS | RPRX | |
|---|---|---|
Market Cap | $59.73B | $25.27B |
Volume | 21,563,700 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $286.69 | $63.96 |
52-Week Low | $73.87 | $35.44 |
Typical Hold Time | 24 Days | 1 Days |
Enterprise Value | $61.86B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $219.71, down 7.32% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth projections ($530M in 2025 to $1.4B in 2026) but thin net margins (3.13%) and elevated valuations (P/E 845). Recent earnings beat expectations in Q1 and Q2 2026, while analyst sentiment remains overwhelmingly bullish with 82% buy ratings and a $288.67 consensus target.
The outlook balances high-growth AI infrastructure demand against execution risks and rich valuations. Near-term support lies at $214, with upside potential to $288 if operational scaling continues. Key risks include competitive pressure, heavy capital expenditure, and insider selling activity noted in recent filings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
